Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Although anti-tumor necrosis factor (TNF) agents have been widely used to treat ulcerative colitis (UC), the real-world incidence of suboptimal response to anti-TNF agents has not been thoroughly investigated, especially among Asians. Methods: Using the Korean National Health Insurance database, we collected data on UC patients who initiated anti-TNF agents between July 1, 2014, and June 30, 2017. We assessed suboptimal responses, including anti-TNF discontinuation or dose escalation, switching to other biologics, augmentation with a non-biologic therapy, and the requirement for colectomy. Results: A total of 1,268 patients were included as new anti-TNF users (infliximab 713, adalimumab 433, golimumab 122). The proportion of patients who experienced at least one suboptimal response within 1 year among all patients was 63.5%, including 59.1%, 69.5%, and 68.0% of patients treated with infliximab, adalimumab, and golimumab, respectively. The cumulative incidences of at least one suboptimal response over time were 41.5%, 63.7%, 80.5%, and 87.1% at 6, 12, 24, and 36 months, respectively. Cox proportional hazards modeling revealed that adalimumab was associated with a higher risk of at least one suboptimal response (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.13 to 1.48), dose escalation (HR, 4.35; 95% CI, 2.97 to 6.38) and discontinuation (HR, 1.25; 95% CI, 1.03 to 1.52) than infliximab. Golimumab was associated with a higher risk of switching to other biologics than infliximab (HR, 1.78; 95% CI, 1.21 to 2.60). Conclusions: More than half of Korean UC patients had suboptimal responses to anti-TNF agents within 1 year. UC patients treated with infliximab might be less prone to suboptimal responses than those treated with adalimumab or golimumab.
Abstract
Background/Aims: Although anti-tumor necrosis factor (TNF) agents have been widely used to treat ulcerative colitis (UC), the real-world incidence of suboptimal response to anti-TNF agents has not been thoroughly investigated, especially among Asians. Methods: Using the Korean National Health Insurance database, we collected data on UC patients who initiated anti-TNF agents between July 1, 2014, and June 30, 2017. We assessed suboptimal responses, including anti-TNF discontinuation or dose escalation, switching to other biologics, augmentation with a non-biologic therapy, and the requirement for colectomy. Results: A total of 1,268 patients were included as new anti-TNF users (infliximab 713, adalimumab 433, golimumab 122). The proportion of patients who experienced at least one suboptimal response within 1 year among all patients was 63.5%, including 59.1%, 69.5%, and 68.0% of patients treated with infliximab, adalimumab, and golimumab, respectively. The cumulative incidences of at least one suboptimal response over time were 41.5%, 63.7%, 80.5%, and 87.1% at 6, 12, 24, and 36 months, respectively. Cox proportional hazards modeling revealed that adalimumab was associated with a higher risk of at least one suboptimal response (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.13 to 1.48), dose escalation (HR, 4.35; 95% CI, 2.97 to 6.38) and discontinuation (HR, 1.25; 95% CI, 1.03 to 1.52) than infliximab. Golimumab was associated with a higher risk of switching to other biologics than infliximab (HR, 1.78; 95% CI, 1.21 to 2.60). Conclusions: More than half of Korean UC patients had suboptimal responses to anti-TNF agents within 1 year. UC patients treated with infliximab might be less prone to suboptimal responses than those treated with adalimumab or golimumab.
참고문헌 (33)
- Magro F, "Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1 : definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders", J Crohns Colitis, 11, pp.649~670 (2017)
- 최창환, "궤양성 대장염 치료 가이드라인 개정판", 대한소화기학회지, 69(1), pp.1~28 (2017), 대한소화기학회[DOI]
- Wee Khoon Ng, "Changing epidemiological trends of inflammatory bowel disease in Asia", Intestinal research, 14(2), pp.111~119 (2016), 대한장연구학회
- Kaplan GG, "Understanding and preventing the global increase of inflammatory bowel disease", Gastroenterology, 152, pp.313~321 (2017)
- Kotze PG, "Progression of inflammatory bowel diseases throughout Latin America and the Caribbean : a systematic review", Clin Gastroenterol Hepatol, 18, pp.304~312 (2020)
- Park SH, "A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong District of Seoul, Korea in 1986-2015", J Crohns Colitis, 13, pp.1410~1417 (2019)
- Kwak MS, "Emerging trends of inflammatory bowel disease in South Korea : a nationwide population-based study", J Gastroenterol Hepatol, 34, pp.1018~1026 (2019)
- Harbord M, "Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2 : current management", J Crohns Colitis, 11, pp.769~784 (2017)
- Xu J, "Trends and factors affecting hospitalization costs in patients with inflammatory bowel disease : a two-center study over the past decade", Gastroenterol Res Pract, 2013, pp.267630~ (2013)
- van der Valk ME, "Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy : results from the COIN study", Gut, 63, pp.72~79 (2014)
- Kim JW, "Long-term evolution of direct healthcare costs for inflammatory bowel diseases : a population-based study(2006-2015)", Scand J Gastroenterol, 54, pp.419~426 (2019)
- Saito S, "Paradigm shift of healthcare cost for patients with inflammatory bowel diseases : a claims data-based analysis in Japan", Gastrointest Disord, 1, pp.120~128 (2019)
- Jooyoung Lee, "Changes in Direct Healthcare Costs before and after the Diagnosis of Inflammatory Bowel Disease: A Nationwide Population-Based Study", Gut and Liver, 14(1), pp.89~99 (2020), 거트앤리버 소화기연관학회협의회
- Pugliese D, "Anti TNF-α therapy for ulcerative colitis : current status and prospects for the future", Expert Rev Clin Immunol, 13, pp.223~233 (2017)
- Bonovas S, "Safety of biological therapies in ulcerative colitis : an umbrella review of meta-analyses", Best Pract Res Clin Gastroenterol, 32-33, pp.43~47 (2018)
- Rubin DT, "Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn’s disease", Aliment Pharmacol Ther, 39, pp.1143~1155 (2014)
- Patel H, "Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn’s disease in the United States", PLoS One, 12, pp.e0175099~ (2017)
- Lindsay JO, "Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease", Dig Liver Dis, 49, pp.1086~1091 (2017)
- Gemayel NC, "Dose escalation and switching of biologics in ulcerative colitis : a systematic literature review in real-world evidence", Curr Med Res Opin, 35, pp.1911~1923 (2019)
- Chen C, "Real-world pattern of biologic use in patients with inflammatory bowel disease : treatment persistence, switching, and importance of concurrent immunosuppressive therapy", Inflamm Bowel Dis, 25, pp.1417~1427 (2019)
- Jang EJ, "A real-world analysis of prescribing patterns and non-persistence of antiTNFα therapy for inflammatory bowel disease", Clin Drug Investig, 39, pp.625~630 (2019)
- Jung YS, "Biologic use patterns and predictors for non-persistence and switching of biologics in patients with inflammatory bowel disease : a nationwide population-based study", Dig Dis Sci, 65, pp.1436~1444 (2020)
- 김지애, "Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data", Journal of Korean Medical Science, 32(5), pp.718~728 (2017), 대한의학회
- 김경훈, "건강보험청구자료에서 동반질환 보정방법", 보건행정학회지, 26(1), pp.71~78 (2016), 한국보건행정학회
- Wolf D, "Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis", Aliment Pharmacol Ther, 40, pp.486~497 (2014)
- Colombel JF, "Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis : data from ULTRA 1, 2, and 3", Am J Gastroenterol, 109, pp.1771~1780 (2014)
- 한민경, "Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study", Yonsei Medical Journal, 61(1), pp.48~55 (2020), 연세대학교의과대학[DOI]
- Vickers AD, "Systematic review with network meta-analysis : comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis", PLoS One, 11, pp.e0165435~ (2016)
- Singh S, "Systematic review with network meta-analysis : first-and second-line pharmacotherapy for moderate-severe ulcerative colitis", Aliment Pharmacol Ther, 47, pp.162~175 (2018)
- Singh S, "First-and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis : an updated network meta-analysis", Clin Gastroenterol Hepatol, 18, pp.2179~2191 (2020)
- Singh S, "comparative risk of serious infections with biologic and", or immunosuppressive therapy in patients with inflammatory bowel diseases : a systematic review and meta-analysis, 2020, pp.18, 69~81
- Singh S, "Comparison of infliximab and adalimumab in biologicnaive patients with ulcerative colitis : a nationwide Danish cohort study", Clin Gastroenterol Hepatol, 15, pp.1218~1225 (2017)
- Chang Kyun Lee, "A new opportunity for innovative inflammatory bowel disease research: the moderate-to-severe ulcerative colitis in Korea (MOSAIK) cohort study", Intestinal research, 17(1), pp.1~5 (2019), 대한장연구학회[DOI]